Entera Bio Ltd. — Director's Dealing 2022

Jan 11, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2022-01-01

Reporting Person: Schwartz Phillip (Director, President of R&D)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares, par value NIS 0.0000769 per share	597410	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$6.31	2023-11-23	Ordinary Shares, par value NIS 0.0000769 per share (357500)		Direct
Stock Option (right to buy)	$3.15	2031-04-21	Ordinary Shares, par value NIS 0.0000769 per share (100000)		Direct

Footnotes

F1: The options vested ratably on a quarterly basis over a four-year period commencing on February 23, 2018.

F2: The options vest over a four-year period that commenced on April 21, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.